New cancer drug ALK-N001 enters early human testing
NCT ID NCT07529535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled, and the study is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALK-N001 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors like esophageal or lung cancer.
What could go wrong
This is a very early Phase 1 trial with only 16 participants, currently suspended. It primarily tests safety and dosing, so it may not lead to an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
Zhongshan Hospital, Fudan University
Shanghai, 200032, China